Vasovagal syncope—also called neurocardiogenic syncope—is a brief loss of consciousness caused by a sudden drop in heart rate and blood pressure usually diagnosed and treated by a cardiologist. Psychiatrists rarely are consulted in such cases, but evidence suggests these patients often have comorbid psychiatric disorders. Psychiatrists can aid cardiologists in treating patients troubled by recurring episodes of vasovagal syncope.

Similar to panic disorder, vasovagal syncope can occur following a trigger or without any warning. After an initial event, vasovagal syncope episodes may never occur again, may occur occasionally, or may be frequent. Cardiologists use Holter monitoring, echocardiography, laboratory testing, stress testing, tilt table monitoring, and other methods to rule out cardiac causes of syncope. For patients whom a cardiac or neurologic cause cannot be determined, there is no recommended treatment, although beta blockers commonly are used.

I suggest a protocol that includes psychiatric evaluation, pharmacotherapy, cognitive-behavioral therapy (CBT), and patient education.

**Psychiatric evaluation.** Because psychiatric disorders often accompany vasovagal syncope, patients should undergo a thorough psychiatric evaluation, and any comorbid psychiatric disorders should be addressed according to current treatment guidelines.

**Pharmacotherapy.** Because serotonin (5-HT) may play a key role in blood pressure regulation and vasovagal syncope, a selective serotonin reuptake inhibitor (SSRI) may be an option. Evidence suggests paroxetine and sertraline may help prevent vasovagal syncope, and other SSRIs may share this benefit. In 1 nonrandomized trial of 74 patients with a history of vasovagal syncope, amitriptyline prevented recurrent episodes. In a small trial, sublingual lorazepam, 2 to 4 mg, prevented vasovagal attacks in patients undergoing a procedure that previously triggered syncope.

**CBT** can help patients identify and modify thoughts that trigger syncope. In a small case series, CBT led to significant reductions in syncopal episodes. Educate patients about environmental triggers of vasovagal events they can avoid, such as dehydration, hot rooms, long periods of standing, and emotional events. Patients who have known triggers that usually cannot be avoided, such as the sight of blood and other conditioned responses, may be helped by behavioral therapies such as systematic desensitization. Patients with known body triggers may be able to take prophylactic medication—for example, patients who are known to faint when nauseous may be able to take prochlorperazine to prevent a syncopal episode.

**Patient education.** Patients who experience presyncopal symptoms such as lightheadedness, visual dimming, nausea, and weakness should be instructed to lie down on the...
Pearls

floor with their legs up at the first sign of an impending episode. If sitting, they can put their head between their knees. Progressive relaxation should be avoided. Patients might be able to block an episode by crossing their legs and tensing their muscles.7

References

Available Online

Effective Strategies for Patients With Complex Depression in Psychiatric Practice

Switch or augment? Lessons from STAR*D
Andrew A. Nierenberg, MD, Associate Director, Depression Clinical and Research Program, Co-Director, Bipolar Clinic and Research Program, Massachusetts General Hospital; Professor of Psychiatry, Harvard Medical School, Boston, Massachusetts

Switching, combination, and augmentation strategies for major depressive disorder
George I. Papakostas, MD, Director, Treatment-Resistant Depression Studies, Massachusetts General Hospital; Associate Professor of Psychiatry, Harvard Medical School, Boston, Massachusetts

Major depressive disorder and other medical illness: A two-way street
Philip R. Muskin, MD, Professor of Clinical Psychiatry, Columbia University; Chief of Service: Consultation-Liaison Psychiatry, Department of Psychiatry, Columbia University Medical Center; Research Psychiatrist, New York State Psychiatric Institute, New York, New York

This supplement was sponsored by SciMed and supported by an educational grant from AstraZeneca. It was peer reviewed by Current Psychiatry.